Karyopharm: Data at AACR from Phase 1 Study of Selinexor in Myelofibrosis

 Updated Safety and Efficacy Data Will be Presented in a Poster Session at AACR 2023 from All Patients Enrolled in the Phase 1 Study –

– Company to Host Investor Webcast Featuring a Key Opinion Leader on April 18, 2023 at 4:30 p.m. ET to Discuss Updated Results –

Karyopharm will host a webcast on, April 18, 2023, at 4:30 p.m. Eastern Time with a key opinion leader to discuss the updated data on selinexor in combination with ruxolitinib as well as the current treatment landscape and unmet medical need in treating patients with myelofibrosis.

To access the event, please dial (888) 349-0102 (local) or (412) 902-4299 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website following the event.

https://www.biospace.com/article/releases/karyopharm-to-present-data-from-phase-1-study-of-selinexor-in-patients-with-treatment-naive-myelofibrosis-at-aacr-and-to-host-investor-webcast-on-april-18th/